|
|
Volumn 16, Issue 7, 2015, Pages e319-
|
|
Nivolumab for squamous-cell non-small-cell lung cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
MONOCLONAL ANTIBODY;
NIVOLUMAB;
TAXOID;
CARCINOMA, NON-SMALL-CELL LUNG;
CARCINOMA, SQUAMOUS CELL;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED STUDY;
DISEASE FREE SURVIVAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
FEMALE;
HUMAN;
KAPLAN MEIER METHOD;
LUNG NEOPLASMS;
MALE;
MORTALITY;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
PROGNOSIS;
PROPORTIONAL HAZARDS MODEL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
TUMOR INVASION;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
BALTIMORE;
CARCINOMA, NON-SMALL-CELL LUNG;
CARCINOMA, SQUAMOUS CELL;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
KAPLAN-MEIER ESTIMATE;
LUNG NEOPLASMS;
MALE;
NEOPLASM INVASIVENESS;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
SURVIVAL ANALYSIS;
TAXOIDS;
|
|
EID: 84942421192
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(15)00033-9 Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|